What's in Bio-Thera Solutions's pipeline?

Bio-Thera Solutions has 21 drugs in our index: 1 marketed, 0 filed, 15 in Phase 3, 1 in Phase 2, 4 in Phase 1.

Which companies overlap with Bio-Thera Solutions's portfolio?

Top competitors by shared drug class: Akeso, Pfizer, Innovent Biologics (Suzhou) Co. Ltd., Janssen Research & Development, LLC, Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bio-thera-solutions.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Bio-Thera Solutions — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bio-Thera Solutions pipeline: 1 marketed, 0 filed, 15 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 15 Phase 3 1 Phase 2 4 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
QLETLI	QLETLI	marketed			Other
BAT3306	BAT3306	phase 3	PD-1 inhibitor	PD-1	Oncology
BAT1706	BAT1706	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β	Oncology
Paclitaxel for Injection	Paclitaxel for Injection	phase 3	Taxane; microtubule stabilizer	β-tubulin; microtubules	Oncology
BAT2506 injection	BAT2506 injection	phase 3	Bispecific checkpoint inhibitor		Oncology
BAT1406	BAT1406	phase 3	Bispecific antibody; PD-1/TGF-β inhibitor	PD-1 and TGF-β	Oncology
BAT2206	BAT2206	phase 3	Bispecific antibody; dual checkpoint inhibitor	Likely PD-1 and LAG-3 (or similar dual checkpoint targets)	Oncology
BAT5906 injection	BAT5906 injection	phase 3	Bispecific checkpoint inhibitor		Oncology
BAT8001 for injection	BAT8001 for injection	phase 3	Bispecific monoclonal antibody		Oncology
EU Avastin®	EU Avastin®	phase 3	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)	Oncology
EU Simponi	EU Simponi	phase 3	TNF-alpha inhibitor	TNF-alpha	Immunology
US-Keytruda®	US-Keytruda®	phase 3	PD-1 inhibitor	PD-1	Oncology

Therapeutic area mix

Oncology · 13
Immunology · 2
Immunology / Gastroenterology / Dermatology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Akeso · 5 shared drug classes
Pfizer · 3 shared drug classes
Innovent Biologics (Suzhou) Co. Ltd. · 3 shared drug classes
Janssen Research & Development, LLC · 3 shared drug classes
Merck Sharp & Dohme LLC · 3 shared drug classes
Eli Lilly and Company · 2 shared drug classes
Celltrion · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Bio-Thera Solutions:

Cite this brief

Drug Landscape (2026). Bio-Thera Solutions — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bio-thera-solutions. Accessed 2026-06-10.